Thinking beyond Bi
What’s next for regulatory, IP reform in China after Bi’s departure
Following the resignation of Jingquan Bi, early signs for continued biopharma regulatory reform in China remain positive. But the IP reforms spearheaded by Bi look to have fallen off the government’s priority list, and there is rising uncertainty about whether biotechnology will be dragged into the discord embroiling the U.S. and China.
China lost a champion of innovative biopharma products when the Politburo Standing Committee announced on Aug. 16 that Bi would resign as secretary at the State Administration of Market and Supervision amid a vaccines manufacturing scandal.
From 2015 until March this year, Bi had served as head of China’s State Drug Administration (SDA, now National Medical Products Administration (NMPA)), where he led the government’s march to bring innovative new drugs to China via a slew of regulatory reforms (see “Opening the Gates in China”).
The result has been an increase in new drug approvals, including six new HCV drugs and the first two checkpoint inhibitors -- Keytruda pembrolizumab from Merck & Co. Inc. and Opdivo nivolumab from Bristol-Myers Squibb Co. and Ono Pharmaceuticals Co. Ltd.
Bi also proposed a patent linkage system, akin to the Hatch-Waxman Act and other laws in the West, and the establishment of six years of data exclusivity for most innovative drugs, with innovative biologics and drugs for rare and pediatric diseases receiving 10 years of exclusivity.
In March, Bi took over the top job at the State Administration of Market and Supervision, where it was expected he would implement these IP reforms. The agency oversees NMPA, the State Intellectual Property Office and other pricing, quality and antitrust functions.
There is already evidence that Hong Jiao, who is now head of NMPA,